Biotechnology News and Research RSS Feed - Biotechnology News and Research

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients. [More]

TxCell reports results from annual general meeting of shareholders

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces results of its annual general meeting of shareholders held in Valbonne, France. [More]
Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

CQDM, Brain Canada and the Ontario Brain Institute award close to $8.5M to six (6) multi-disciplinary and multi-provincial research teams across Canada to address unmet needs in neuroscience within their Focus on Brain strategic initiative. To this amount, $1.5M is added from the various research entities involved as in-kind contributions. [More]
Ceres receives U.S. patent for genetic sequence obtained from soybean

Ceres receives U.S. patent for genetic sequence obtained from soybean

Ceres, Inc., an agricultural biotechnology company, has been awarded a U.S. patent for a genetic sequence derived from soybean, covering uses of the gene in areas such as research, product development and plant transformation. [More]
Scorpion venom could kill cancer cells

Scorpion venom could kill cancer cells

When the toxin invades channels in the cells with this disease produces cellular damage until killing them. [More]
New tool could help identify pathogens in food and beverages

New tool could help identify pathogens in food and beverages

Researchers at the National Polytechnic Institute (IPN) in Mexico, developed a technology capable of identifying pathogens in food and beverages. This technique could work in the restaurant industry as a biosensor to detect in what conditions food is before being eaten in order to avoid possible gastrointestinal diseases. [More]
Study explores how our intestinal tract changes as we age

Study explores how our intestinal tract changes as we age

Scientists and clinicians on the Norwich Research Park have carried out the first detailed study of how our intestinal tract changes as we age, and how this determines our overall health. [More]
Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression. [More]
Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Discovery Laboratories, Inc., a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported that the first patient has been enrolled in the next phase of its phase 2a clinical evaluation of AEROSURF, which is designed to evaluate the safety and tolerability of higher and repeat doses of aerosolized KL4 surfactant administered to premature infants 29 to 34 weeks gestational age (GA) who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to infants receiving nCPAP alone. [More]
DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM). [More]
ORIG3N, LabCorp form strategic partnership

ORIG3N, LabCorp form strategic partnership

ORIG3N, Inc., a pioneer in regenerative medicine and provider of induced pluripotent stem cell (iPSC) storage, called LifeCapsule, today announced a strategic collaboration with Laboratory Corporation of America Holdings. [More]
Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

Cryoport, Inc. today announced financial results for the three and twelve-month periods ended March 31, 2015. [More]
BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform. [More]
Simple blood test can predict evidence of TBI on radiographic imaging, injury severity

Simple blood test can predict evidence of TBI on radiographic imaging, injury severity

New study results show that a simple blood test to measure brain-specific proteins released after a person suffers a traumatic brain injury (TBI) can reliably predict both evidence of TBI on radiographic imaging and injury severity. [More]
Acupuncture reduces pain, inflammation in pediatric patients with acute appendicitis

Acupuncture reduces pain, inflammation in pediatric patients with acute appendicitis

Acupuncture was shown to lessen pain and reduce the underlying inflammation in pediatric patients with a diagnosis of acute appendicitis, according to a study published in the Journal of Alternative and Complementary Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. [More]
Denali launched to discover, develop effective medicines for neurodegenerative diseases

Denali launched to discover, develop effective medicines for neurodegenerative diseases

Denali Therapeutics Inc., a new biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that it has launched with an initial investment commitment of $217 million. [More]
BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015. [More]
LABINDIA to promote Dotmatics’ scientific informatics solutions, services in India

LABINDIA to promote Dotmatics’ scientific informatics solutions, services in India

Dotmatics, the leading provider of scientific informatics solutions and services for the pharma, biotech, chemicals, agrochemicals and academia announced today that it has appointed LABINDIA as a distributor in India. [More]
Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

In a new study published in the Protein & Cell, Chen-Yu Zhang's group at Nanjing University reports that small non-coding RNAs in maternal food can transfer through placenta to regulate fetal gene expression. [More]
Advertisement
Advertisement